Phase 1 study to investigate the pharmacokinetic properties of dacomitinib in healthy adult Chinese subjects genotyped for CYP2D6-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Phase 1 study to investigate the pharmacokinetic properties of dacomitinib in healthy adult Chinese subjects genotyped for CYP2D6

Published:2017-08-18 Issue:5 Volume:48 Page:459-466
ISSN:0049-8254
Container-title:Xenobiotica
language:en
Short-container-title:Xenobiotica

Author:

Chen Xia¹²,Jiang Ji¹²,Giri Nagdeep³,Hu Pei¹²

Affiliation:

1. Phase I Unit, Clinical Pharmacological Research Centre, Peking Union Medical College Hospital, Xicheng District, Beijing, China,

2. Beijing Key Laboratory of Clinical PK and PD Investigation for Innovative Drugs, Beijing, China, and

3. Pfizer Inc., La Jolla, CA, USA

Publisher

Informa UK Limited

Subject

Health, Toxicology and Mutagenesis,Pharmacology,Toxicology,Biochemistry,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/00498254.2017.1342881

Reference14 articles.

1. A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck

2. Differences in Cytochrome P450-Mediated Pharmacokinetics Between Chinese and Caucasian Populations Predicted by Mechanistic Physiologically Based Pharmacokinetic Modelling

3. The effect of dacomitinib (PF-00299804) on CYP2D6 activity in healthy volunteers who are extensive or intermediate metabolizers

4. A phase I, open-label, mass balance study of [14C] dacomitinib (PF-00299804) in healthy male volunteers

5. Pharmacogenetics of CYP2D6 and tamoxifen therapy: Light at the end of the tunnel?

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Doses Evaluated in Clinical Pharmacology Studies Investigating the Effect of Intrinsic and Extrinsic Factors on PK and Safety: Case Examples from Approved Drug Development Programs;The AAPS Journal;2024-06-17

2. Protein Kinase Inhibitors Indicated for Lung Cancer: Pharmacodynamics, Pharmacokinetics, Adverse Drug Reactions, and Evaluation in Clinical Trials;Journal of Clinical Pharmacy and Therapeutics;2024-01

3. Plasma exchange treats severe intrahepatic cholestasis caused by dacomitinib: A case report;Medicine;2022-07-08

4. Integration of liquid biopsy and pharmacogenomics for precision therapy of EGFR mutant and resistant lung cancers;Molecular Cancer;2022-02-24

5. Effects of CYP2D6 Genetic Polymorphism and Drug Interaction on the Metabolism of Dacomitinib;Chemical Research in Toxicology;2021-12-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3